Efficacy and Safety of the Bruton ' s Tyrosine Kinase Inhibit or Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension

Authors
Category Primary study
JournalNeurology
Year 2023
This article has no abstract
Epistemonikos ID: 475d29c1d669788325bc2904f68e38f3416bf897
First added on: Feb 16, 2025